Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection

AIDS Res Hum Retroviruses. 2001 Jan 20;17(2):137-46. doi: 10.1089/08892220150217229.

Abstract

We evaluated 16 antibody assays for their performance in discriminating recent from established HIV-1 infection. These approaches were based on antigen specificity, quantity, conformation dependence, and avidity/affinity of HIV-specific antibodies. A panel of 41 sera from subjects who had seroconverted in the previous 2-6 months (n = 20) and from subjects with established infection (>1 year, n = 21) were run in each assay. Compared with anti-Gag and anti-Pol responses, quantitative anti-Env antibody levels were initially lower and ultimately higher, resulting in the greatest spread and least overlap between incident and established infection. Quantitative measurement included end-point titer in Western blot, end-point titer or response at a given dilution in solid-phase enzyme immunoassays (EIAs) with recombinant proteins or synthetic peptides, and IgG capture assays that reflect the relative proportion of IgG that is anti-HIV antibody. Focusing on the anti-env response, we measured specific responses to the V3 region of gp120, to the CD4-binding site of gp120, to a peptide corresponding to the immunodominant region of gp41, and to conformation-dependent epitopes of gp120. We also measured antibody affinity for gp41 peptide and the relative avidity for gp120 or gp41 peptide by thermal or urea-elution assays. These assays also discriminated recent from established infection but were not necessarily superior to the quantitative anti-Env assays. Appropriate approaches, based on distinct principles or combination of principles, can be used to develop simple assays for identifying individuals recently infected with HIV-1.

Publication types

  • Comparative Study

MeSH terms

  • Antibody Affinity
  • CD4 Antigens / immunology
  • Diagnosis, Differential
  • Epitopes / immunology
  • Gene Products, gag / immunology
  • Gene Products, pol / immunology
  • HIV Antibodies / blood
  • HIV Antibodies / immunology*
  • HIV Antigens / immunology
  • HIV Envelope Protein gp120 / immunology
  • HIV Envelope Protein gp41 / immunology
  • HIV Infections / blood
  • HIV Infections / diagnosis*
  • HIV Seropositivity / blood
  • HIV Seropositivity / diagnosis*
  • HIV-1 / immunology*
  • Humans
  • Immunodominant Epitopes / immunology
  • Immunoenzyme Techniques
  • Peptide Biosynthesis
  • Protein Conformation
  • Recombinant Proteins / immunology

Substances

  • CD4 Antigens
  • Epitopes
  • Gene Products, gag
  • Gene Products, pol
  • HIV Antibodies
  • HIV Antigens
  • HIV Envelope Protein gp120
  • HIV Envelope Protein gp41
  • Immunodominant Epitopes
  • Recombinant Proteins